Medicine and Health

Efficacy and safety of pomalidomide, bortezomib, and dexamethasone combination chemotherapy for newly diagnosed multiple myeloma: POMACE Phase II Study

F. Saj, Y. Nisha, et al.

This phase 2 study conducted by Fen Saj, Yadav Nisha, Prasanth Ganesan, Smita Kayal, Rakhee Kar, Dhanapathi Halanaik, and Biswajit Dubashi reveals that the combination of bortezomib, pomalidomide, and dexamethasone for newly diagnosed multiple myeloma is not only effective—boasting a 100% overall response rate—but also safe, leading to significantly improved patient outcomes. Further phase 3 studies are encouraged.

00:00

Playback language: English

Index

Abstract

This phase 2 study evaluated the efficacy and safety of bortezomib, pomalidomide, and dexamethasone (VPd) induction for newly diagnosed multiple myeloma (NDMM). Thirty-four transplant-eligible and ineligible patients received four cycles of VPd. The overall response rate was 100%, with 87% achieving ≥VGPR (primary endpoint). Common toxicities included anemia, peripheral neuropathy, and constipation. Patients with ≥VGPR had significantly better 12-month PFS and OS than those with PR. The study suggests VPd is safe and efficacious in NDMM, warranting further phase 3 studies.

Publisher

Blood Cancer Journal

Published On

Jan 01, 2023

Authors

Fen Saj, Yadav Nisha, Prasanth Ganesan, Smita Kayal, Rakhee Kar, Dhanapathi Halanaik, Biswajit Dubashi

Related Publications

Explore these studies to deepen your understanding of the subject.

Medicine and Health

Efficacy and safety of serplulimab plus nab-paclitaxel in previously treated patients with PD-L1-positive advanced cervical cancer: a phase II, single-arm study

J. An, X. Li, et al.

Medicine and Health

A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression

P. R. Shiroma, P. Thuras, et al.

Medicine and Health

Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy after immune checkpoint inhibitor administration for advanced non-small cell lung cancer: A multicenter Phase 2 clinical trial

T. Sonoda, Y. Umeda, et al.

Medicine and Health

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial

X. Leleu, C. Hulin, et al.

Listen, Learn & Level Up

Over 10,000 hours of research content in 25+ fields, available in 12+ languages.

No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.

listen to research audio papers with researchbunny